Evaluation of prosthetic functionality
Prosthetic valve dysfunction occurred in 18 patients (22.5%), without a difference between patients treated with biological vs. mechanical valve prostheses (p = 0.96). The main complications were anterior paravalvular leak with a frequency of (15%).
The proportion of prosthetic valve dysfunction at 12 years after AVR is 75% for patients with bioprostheses (95% CI = 0.49-0.93) and 50% for mechanical prostheses (95% CI = 0.19 -0.88). The Wilcoxon test did not show statistical significance between the percentages of prosthetic dysfunction over time (p = 0.45). The restricted mean prosthetic dysfunction was 11.4 years for patients with biological prostheses and 19.4 years for mechanical prostheses. The Cox proportional hazards analysis in post-AVR patients is shown in Table 4.
Prosthetic valve dysfunction is shown in Tables 5 and 6. Patients who were implanted with locally manufactured bioprostheses (INC valve) did not show differences in cytokine levels, echocardiographic parameters, or prosthetic valve dysfunction than imported bioprostheses Table 7. Figure 2 show survival of functionality and we included a Graphical abstract